- Allison Rosenthal appointed
Chief Commercial Officer to lead the potential commercial launch
of MDMA-assisted therapy if approved by the FDA
- Coy Stout joins as Vice President of Market
Access
SAN JOSE, Calif., May 3, 2024 /PRNewswire/ -- Lykos
Therapeutics ("Lykos"), a company dedicated to transforming mental
healthcare, announced Allison
Rosenthal has been appointed Chief Commercial Officer (CCO)
and member of the Company's executive committee effective
immediately. As the lead for the Company's commercial strategy and
operations, she will have an initial focus on the potential launch
of midomafetamine (MDMA) capsules, if approved by the U.S. Food and
Drug Administration ("FDA"), to be used in combination with
psychological intervention ("MDMA-assisted therapy"). Coy Stout has
also joined Lykos as Vice President (VP) of Market Access, a
critical function in the growing commercial organization.
"The appointment of Allison, our first chief commercial officer,
marks a critical milestone as we build out our commercial
organization and prepare for a potential product launch of
MDMA-assisted therapy if approved by the FDA," said Amy Emerson, Chief Executive Officer of Lykos
Therapeutics. "In addition, Coy, a seasoned professional who has
successfully led access and reimbursement efforts for more than 30
product launches, joins to establish a patient access program in
advance of a potential FDA approval of MDMA-assisted
therapy."
Ms. Rosenthal brings to Lykos more than 25 years of
pharmaceutical experience introducing innovative therapies. Most
recently, Ms. Rosenthal was Head of the U.S. Neuroscience Sales and
Marketing for Otsuka, where she was responsible for leading,
developing and executing effective commercial strategies for
Otsuka's U.S. business with an organization of nearly 1,000 people
and sales approaching $1.5 billion.
Before joining Otsuka U.S., Ms. Rosenthal was General Manager of
Otsuka Canada for eight years,
during which time she led the early asset and development team for
Otsuka global marketing. Before Otsuka, Ms. Rosenthal spent 18
years at Bristol-Myers Squibb in roles with increasing levels of
responsibility. She has a bachelor's degree in Anatomical Sciences
and a master's degree in Anatomy and Cell Biology, both from McGill
University of Montreal.
Mr. Stout brings over 25 years of experience as a leader in the
biopharmaceutical industry, having established reimbursement,
distribution and patient support programs to help advance patient
access in the U.S. for important medications across multiple
therapeutic areas with high unmet needs and social stigma. Before
joining Lykos, Mr. Stout served as the Senior Vice President of
Patient Advocacy and Policy at Brii Biosciences for two and a half
years. Before Brii Biosciences, Mr. Stout had a 17-year tenure at
Gilead where he last served as VP of Market Access Strategy and
Account Management. In addition to his expertise in drug coverage,
innovative payment models and patient support programs, Mr. Stout
has successfully led access and reimbursement efforts for more than
30 product launches. Mr. Stout received his bachelor's degree in
psychology and master's degree in social work from the University of Alabama, and he earned a doctorate in
social work from Simmons University.
Midomafetamine (MDMA) capsules have not been approved by any
regulatory agency. The safety and efficacy of midomafetamine have
not been established for the treatment of PTSD. Investigational
midomafetamine is also being studied in other
indications.
Lykos Therapeutics
At Lykos Therapeutics, a public benefit corporation (PBC) founded
by MAPS, our mission is to transform mental healthcare. We're
applying our decades of evidence-based research to develop
investigational psychedelics to catalyze therapeutic approaches for
mental health conditions. We are relentlessly exploring and
reimagining novel approaches to address unmet needs in the mental
healthcare space, with an initial focus on PTSD. As a PBC, we are
focused on delivering positive impact on our people, communities
and society. To learn more visit us at www.lykospbc.com and on
LinkedIn, X, Instagram and Facebook.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lykos-therapeutics-strengthens-commercial-organization-with-key-hires-as-it-prepares-for-potential-commercial-launch-302135259.html
SOURCE Multidisciplinary Association for Psychedelic Studies /
KCSA